Cargando…

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

BACKGROUND: A phase III trial in Japan showed that pirfenidone is effective for idiopathic pulmonary fibrosis (IPF). To find out which patients specifically benefit from pirfenidone, we analyzed in an exploratory manner the data from the phase III trial. METHODS: The patients in the phase III trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azuma, Arata, Taguchi, Yoshio, Ogura, Takashi, Ebina, Masahito, Taniguchi, Hiroyuki, Kondoh, Yasuhiro, Suga, Moritaka, Takahashi, Hiroki, Nakata, Koichiro, Sato, Atsuhiko, Kudoh, Shoji, Nukiwa, Toshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216874/ https://www.ncbi.nlm.nih.gov/pubmed/22035508 http://dx.doi.org/10.1186/1465-9921-12-143

Ejemplares similares

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
por: Taniguchi, Hiroyuki, et al.
Publicado: (2011)

Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan
por: Ikeda, Kimiyuki, et al.
Publicado: (2020)

Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia – short term evaluation of safety and tolerability
por: Kamio, Koichiro, et al.
Publicado: (2014)

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023)

A Case of Cutaneous Infection Caused by Mycobacterium Szulgai with Progression to Acute Respiratory Distress Syndrome
por: Ohta, Hiromitsu, et al.
Publicado: (2011)

Primary ciliary dyskinesia caused by a large homozygous deletion including exons 1–4 of DRC1 in Japanese patients with recurrent sinopulmonary infection
por: Keicho, Naoto, et al.
Publicado: (2019)

Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2014)

Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function
por: Nakamura, Atsushi, et al.
Publicado: (2013)

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
por: Cottin, Vincent, et al.
Publicado: (2018)

Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

A Normal Range of KL-6/MUC1 Independent of Elevated SP-D Indicates a Better Prognosis in the Patients with Honeycombing on High-Resolution Computed Tomography
por: Hisata, Shu, et al.
Publicado: (2011)

Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

Gradual Increase of High Mobility Group Protein B1 in the Lungs after the Onset of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Ebina, Masahito, et al.
Publicado: (2011)

Increased Susceptibility to LPS-induced Endotoxin Shock in Secretory Leukoprotease Inhibitor (SLPI)-deficient Mice
por: Nakamura, Akira, et al.
Publicado: (2003)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Epimorphin expression in interstitial pneumonia
por: Terasaki, Yasuhiro, et al.
Publicado: (2005)

The negative effect of initial high-dose methylprednisolone and tapering regimen for acute respiratory distress syndrome: a retrospective propensity matched cohort study
por: Takaki, Makoto, et al.
Publicado: (2017)

Pirfenidone-induced Eosinophilic Pleurisy
por: Hase, Isano, et al.
Publicado: (2017)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
por: Jiang, Zhaosheng, et al.
Publicado: (2022)

Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
por: Minegishi, Yuji, et al.
Publicado: (2020)

Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation
por: Kamio, Koichiro, et al.
Publicado: (2018)

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
por: Sakayori, Masashi, et al.
Publicado: (2019)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Role of pirfenidone in the management of pulmonary fibrosis
por: Meyer, Keith C, et al.
Publicado: (2017)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Interstitial lung disease associated with drug therapy
por: Camus, P, et al.
Publicado: (2004)

Gene Mutations in Lung Cancer: Promising Predictive Factors for the Success of Molecular Therapy
por: Inoue, Akira, et al.
Publicado: (2005)

A randomized controlled phase III trial protocol: perioperative pirfenidone therapy in patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis to confirm the preventative effect against postoperative acute exacerbation: the PIII-PEOPLE study (NEJ034)
por: Sakairi, Yuichi, et al.
Publicado: (2023)

The multifaceted role of pirfenidone and its novel targets
por: Macías-Barragán, José, et al.
Publicado: (2010)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Pirfenidone prevents acute kidney injury in the rat
por: Lima-Posada, Ixchel, et al.
Publicado: (2019)

Pirfenidone normalizes the tumor microenvironment to improve chemotherapy
por: Polydorou, Christiana, et al.
Publicado: (2017)

Pirfenidone ameliorates the formation of choroidal neovascularization in mice
por: Bao, Yueqi, et al.
Publicado: (2020)

Pirfenidone regulates LPS mediated activation of neutrophils
por: Evani, Shankar J., et al.
Publicado: (2020)

Severe Photosensitivity Reaction After Pirfenidone Use
por: Choudhury, Saiara, et al.
Publicado: (2021)

Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ests0auds348j10fsn4nkb2gp